Share on StockTwits

Equities research analysts at Laidlow & Co. started coverage on shares of ISIS Pharmaceuticals (NASDAQ:ISIS) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $52.00 price target on the stock. Laidlow & Co.’s price target would suggest a potential upside of 49.47% from the company’s current price.

The analysts wrote, “ISIS is the pioneer and leader in developing antisense technology and owns comprehensive intellectual property estates in the space. In addition, the company continues to improve the technology as the latest generation 2.5 antisense products possess substantially improved potency and enhanced therapeutic index”

A number of other firms have also recently commented on ISIS. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $35.00 price target on the stock. Analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $42.64.

In other ISIS Pharmaceuticals news, CEO Stanley T. Crooke sold 16,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $30.53, for a total transaction of $488,480.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 0.75% during mid-day trading on Tuesday, hitting $34.5299. 752,597 shares of the company’s stock traded hands. ISIS Pharmaceuticals has a one year low of $22.25 and a one year high of $62.66. The stock’s 50-day moving average is $32.17 and its 200-day moving average is $37.56. The company’s market cap is $4.065 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. Analysts expect that ISIS Pharmaceuticals will post $-0.73 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.